GSK (NYSE:GSK) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Posted by Francis Steltz on Oct 29th, 2026

Shares of GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $49.57 and traded as low as $47.36. GSK shares last traded at $48.7080, with a volume of 8,115,867 shares trading hands.

GSK News Roundup

Here are the key news stories impacting GSK this week:

Positive Sentiment: Third-quarter results exceeded expectations: Adjusted earnings were approximately $1.47 per ADR, above the $1.40 consensus, while revenue rose about 4% year over year to roughly $11.8 billion. GSK maintained its full-year targets. GSK beats third-quarter profit estimates, keeps annual targets
Positive Sentiment: Specialty medicines remained the growth engine: HIV, oncology and respiratory products delivered strong or double-digit growth, offsetting weaker vaccines and broadly flat general-medicine sales. GSK Sales Get Boost From Specialty Medicines
Positive Sentiment: Oncology expansion offers longer-term upside: GSK plans to nearly double the number of cancer drugs in trials next year following recent dealmaking. The company also expects another oncology approval, potentially broadening its growth pipeline. GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
Neutral Sentiment: Hepatitis B launch preparation: GSK is preparing a concentrated U.S. launch for Hibsago, its newly approved hepatitis B vaccine, which could provide a future boost to the vaccine portfolio but will require successful commercial execution. Hibsago prepares for U.S. hepatitis B launch
Negative Sentiment: Vaccine weakness overshadowed the earnings beat: Declining adult demand led vaccine revenue to miss expectations, raising concerns about the pace of recovery in a historically important business. GSK shares slide after weaker vaccine sales
Negative Sentiment: Cost and pipeline concerns persist: Mounting costs and questions about the strength of GSK’s future pipeline reduced the market’s enthusiasm for the solid quarter, leaving investors focused on whether specialty-drug growth can sustainably offset vaccine pressure. GSK shares decline as weaker sales and mounting costs concern investors

Wall Street Analyst Weigh In

Several brokerages have commented on GSK. HSBC reissued a “hold” rating on shares of GSK in a research report on Thursday, September 10th. Wolfe Research initiated coverage on GSK in a report on Friday, October 9th. They issued an “outperform” rating and a $70.00 price objective for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of GSK in a research report on Tuesday, September 29th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and set a $55.90 target price on the stock. in a research report on Thursday. Finally, Citigroup initiated coverage on GSK in a research report on Friday, July 24th. They set a “neutral” rating for the company. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $55.48.

Check Out Our Latest Research Report on GSK

GSK Stock Down 4.4%

The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm’s 50 day moving average is $49.57 and its two-hundred day moving average is $52.35. The firm has a market capitalization of $98.52 billion, a P/E ratio of 15.23, a PEG ratio of 2.28 and a beta of 0.33.

GSK (NYSE:GSK – Get Free Report) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. During the same period in the previous year, the company earned $0.47 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Summit Global Investments raised its holdings in GSK by 123.5% in the 3rd quarter. Summit Global Investments now owns 46,599 shares of the pharmaceutical company’s stock valued at $2,245,000 after acquiring an additional 25,747 shares during the period. Aprio Wealth Management LLC lifted its position in GSK by 19.2% during the third quarter. Aprio Wealth Management LLC now owns 9,318 shares of the pharmaceutical company’s stock worth $449,000 after acquiring an additional 1,504 shares during the last quarter. Soltis Investment Advisors LLC acquired a new stake in GSK during the third quarter worth approximately $246,000. Founders Financial Securities LLC boosted its holdings in shares of GSK by 1.0% during the third quarter. Founders Financial Securities LLC now owns 21,884 shares of the pharmaceutical company’s stock worth $1,054,000 after acquiring an additional 211 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of GSK during the third quarter worth approximately $494,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

(Get Free Report)

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.